[225Ac]Ac-DOTATATE
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for [225Ac]Ac-DOTATATE, covering 2025-06-26 to 2026-02-17. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment [Phase 1]